CU20190078A7 - Péptidos útiles en el tratamiento de diabetes - Google Patents
Péptidos útiles en el tratamiento de diabetesInfo
- Publication number
- CU20190078A7 CU20190078A7 CU2019000078A CU20190078A CU20190078A7 CU 20190078 A7 CU20190078 A7 CU 20190078A7 CU 2019000078 A CU2019000078 A CU 2019000078A CU 20190078 A CU20190078 A CU 20190078A CU 20190078 A7 CU20190078 A7 CU 20190078A7
- Authority
- CU
- Cuba
- Prior art keywords
- diabetes
- treatment
- useful peptides
- peptides
- useful
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000001461 cytolytic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
Abstract
<p>La invención se refiere a péptidos tales como HCPYCSLQPLALEGSLQKRG, útiles en el tratamiento de diabetes tipo 1 y a la generación de célula T CD4+ citolítica.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17160085 | 2017-03-09 | ||
PCT/EP2018/055501 WO2018162498A1 (en) | 2017-03-09 | 2018-03-06 | Peptides and methods for the treatment of diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20190078A7 true CU20190078A7 (es) | 2020-04-02 |
CU24596B1 CU24596B1 (es) | 2022-05-11 |
Family
ID=58266442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2019000078A CU24596B1 (es) | 2017-03-09 | 2018-03-06 | Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes |
Country Status (21)
Country | Link |
---|---|
US (4) | US10808016B2 (es) |
EP (1) | EP3592765A1 (es) |
JP (2) | JP7102430B2 (es) |
KR (1) | KR20190126798A (es) |
CN (1) | CN110536898B (es) |
AU (2) | AU2018229741B2 (es) |
BR (1) | BR112019018616A2 (es) |
CA (1) | CA3051518A1 (es) |
CO (1) | CO2019009080A2 (es) |
CU (1) | CU24596B1 (es) |
IL (1) | IL268874B2 (es) |
MX (1) | MX2019010558A (es) |
MY (1) | MY192295A (es) |
NZ (1) | NZ755744A (es) |
PE (1) | PE20191529A1 (es) |
PH (1) | PH12019502036A1 (es) |
RU (1) | RU2761653C2 (es) |
SA (1) | SA519410007B1 (es) |
SG (1) | SG11201908275XA (es) |
WO (1) | WO2018162498A1 (es) |
ZA (1) | ZA201905851B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2476435T3 (pl) | 2006-08-11 | 2018-05-30 | Life Sciences Research Partners Vzw | Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych |
EP3075391A1 (en) * | 2008-02-14 | 2016-10-05 | Life Sciences Research Partners VZW | Strategies to prevent and/or treat immune responses to soluble allofactors |
GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
CU24596B1 (es) | 2017-03-09 | 2022-05-11 | Imcyse Sa | Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes |
AU2020392512A1 (en) | 2019-11-27 | 2022-05-26 | Imcyse Sa | Methods for stratifying diabetes patients |
AU2021208602A1 (en) * | 2020-05-06 | 2022-12-15 | Imcyse Sa | Combination treatment for fumarate-related diseases |
EP4146254A1 (en) | 2020-05-06 | 2023-03-15 | Imcyse SA | Immunogenic peptides with extended oxidoreductase motifs |
EP4347020A1 (en) | 2021-06-01 | 2024-04-10 | Imcyse SA | Improved methods of treatment using immunogenic peptides |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2623391A1 (en) * | 2005-09-22 | 2007-03-29 | Yeda Research Development Co. Ltd. | Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom |
PL2476435T3 (pl) | 2006-08-11 | 2018-05-30 | Life Sciences Research Partners Vzw | Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych |
ES2627882T3 (es) | 2008-02-14 | 2017-07-31 | Life Sciences Research Partners Vzw | Control inmunogénico de tumores y células tumorales |
AU2009214038B2 (en) | 2008-02-14 | 2013-08-22 | Katholieke Universiteit Leuven | Elimination of immune responses to viral vectors |
EP2245059B1 (en) * | 2008-02-14 | 2017-09-20 | Life Sciences Research Partners VZW | Cd4+ t-cells with cytolytic properties |
ES2626115T3 (es) | 2008-02-14 | 2017-07-24 | Life Sciences Research Partners Vzw | Péptidos inmunogénicos y su uso en trasplante |
US20120009678A1 (en) | 2008-02-14 | 2012-01-12 | Jean-Marie Saint-Remy | Immunotherapy targeting intracellular pathogens |
EP3075391A1 (en) | 2008-02-14 | 2016-10-05 | Life Sciences Research Partners VZW | Strategies to prevent and/or treat immune responses to soluble allofactors |
WO2011120994A1 (en) | 2010-03-29 | 2011-10-06 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof |
GB201201511D0 (en) * | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
GB201309469D0 (en) * | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
TR201908418T4 (tr) | 2013-11-04 | 2019-07-22 | Uti Lp | Sürdürülebilir immünoterapi için yöntem ve kompozisyonlar. |
GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
CU24596B1 (es) | 2017-03-09 | 2022-05-11 | Imcyse Sa | Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes |
US20210401976A1 (en) * | 2018-11-12 | 2021-12-30 | Imcyse Sa | Immunogenic peptides with improved oxidoreductase motifs |
TWM593454U (zh) | 2019-11-11 | 2020-04-11 | 競泰股份有限公司 | 多鑰匙鎖心 |
-
2018
- 2018-03-06 CU CU2019000078A patent/CU24596B1/es unknown
- 2018-03-06 PE PE2019001772A patent/PE20191529A1/es unknown
- 2018-03-06 RU RU2019126232A patent/RU2761653C2/ru active
- 2018-03-06 SG SG11201908275X patent/SG11201908275XA/en unknown
- 2018-03-06 CN CN201880016679.XA patent/CN110536898B/zh active Active
- 2018-03-06 CA CA3051518A patent/CA3051518A1/en active Pending
- 2018-03-06 KR KR1020197026399A patent/KR20190126798A/ko active IP Right Grant
- 2018-03-06 JP JP2019548574A patent/JP7102430B2/ja active Active
- 2018-03-06 MX MX2019010558A patent/MX2019010558A/es unknown
- 2018-03-06 AU AU2018229741A patent/AU2018229741B2/en active Active
- 2018-03-06 WO PCT/EP2018/055501 patent/WO2018162498A1/en active Application Filing
- 2018-03-06 EP EP18709553.4A patent/EP3592765A1/en active Pending
- 2018-03-06 MY MYPI2019005150A patent/MY192295A/en unknown
- 2018-03-06 IL IL268874A patent/IL268874B2/en unknown
- 2018-03-06 NZ NZ755744A patent/NZ755744A/en unknown
- 2018-03-06 BR BR112019018616A patent/BR112019018616A2/pt unknown
-
2019
- 2019-08-05 US US16/531,276 patent/US10808016B2/en active Active
- 2019-08-22 ZA ZA2019/05851A patent/ZA201905851B/en unknown
- 2019-08-22 CO CONC2019/0009080A patent/CO2019009080A2/es unknown
- 2019-09-02 SA SA519410007A patent/SA519410007B1/ar unknown
- 2019-09-06 PH PH12019502036A patent/PH12019502036A1/en unknown
-
2020
- 2020-09-14 US US17/019,695 patent/US11407795B2/en active Active
-
2021
- 2021-12-02 AU AU2021277735A patent/AU2021277735A1/en not_active Abandoned
-
2022
- 2022-06-30 US US17/854,190 patent/US11760782B2/en active Active
- 2022-07-05 JP JP2022108398A patent/JP2022125216A/ja active Pending
-
2023
- 2023-08-08 US US18/446,172 patent/US20240092843A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20190078A7 (es) | Péptidos útiles en el tratamiento de diabetes | |
AR113881A1 (es) | Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia | |
PH12017502255A1 (en) | Nrf2 regulators | |
MX371187B (es) | Péptidos terapéuticos. | |
TW201614072A (en) | CAR-T lymphocytes engineered to home to lymph node B cell zone, skin, or gastrointestinal tract | |
EA201592103A3 (ru) | Способы и композиции для усиления cd4+ регуляторных t-клеток | |
PH12016501151A1 (en) | Nrf2 regulators | |
NI201300143A (es) | Coagonista del receptor de glucagón/glp-1 | |
PE20160179A1 (es) | Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido | |
BR112017010173A2 (pt) | composição para tratamento de tecido | |
DOP2016000042A (es) | Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos | |
MA38860B1 (fr) | Cellule progénitrice immuno-modulatrice (imp) | |
ES2693321T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
CY1124761T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος | |
MX2022013454A (es) | Moduladores de la actividad del complemento. | |
TR201901003T4 (tr) | Kumaş İşleme Bileşimi | |
MX2018004121A (es) | Receptores de antigeno y usos de los mismos. | |
EA201700136A1 (ru) | Полимерная композиция для слоя элемента слоя | |
EA201890439A1 (ru) | ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА) | |
BR112017009289A2 (pt) | métodos de administrar composições de amantadina | |
MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
EP4295914A3 (en) | Genetically-engineered drug resistant t cells and methods of using the same | |
SV2017005585A (es) | Peptidos lipidados resistentes a proteasas | |
CY1120843T1 (el) | Πεπτιδια me ανταγωνιστικες δραστικοτητες εναντι φυσικου cxcr4 | |
IN2014CH00151A (es) |